Armstrong Fleming & Moore’s Eli Lilly LLY Stock Holding History

Armstrong Fleming & Moore’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$855K	Buy	929 +33	+4%	+$33.5K	0.36%	45
2025 Q4	$963K	Hold	896	–	–	0.45%	37
2025 Q3	$684K	Buy	896 +140	+19%	+$104K	0.33%	47
2025 Q2	$590K	Buy	756 +501	+196%	+$389K	0.32%	51
2025 Q1	$211K	Sell	255 -501	-66%	-$417K	0.26%	75
2024 Q4	$584K	Hold	756	–	–	0.35%	45
2024 Q3	$670K	Sell	756 -74	-9%	-$66.5K	0.39%	44
2024 Q2	$752K	Buy	830 +13	+2%	+$10.4K	0.48%	40
2024 Q1	$636K	Buy	817 +57	+8%	+$40.6K	0.44%	42
2023 Q4	$443K	Hold	760	–	–	0.33%	60
2023 Q3	$408K	Hold	760	–	–	0.4%	56
2023 Q2	$357K	Buy	+760	New	+$319K	0.33%	61

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $84.5B AUM 11.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Armstrong Fleming & Moore's LLY Position: Q1 2026 in Review

Armstrong Fleming & Moore increased its Eli Lilly (LLY) stake by 3.7% in Q1 2026, buying an estimated $33.5K and bringing the position to 929 shares worth $855K. The position accounts for 0.36% of the portfolio, ranked #45.

Armstrong Fleming & Moore first reported a position in LLY in Q2 2023 and has held it in 12 quarters since. The position peaked at $963K in Q4 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

Armstrong Fleming & Moore held 929 shares of Eli Lilly worth $855K as of Q1 2026.
Armstrong Fleming & Moore bought 33 Eli Lilly shares in Q1 2026, an estimated $33.5K.
Eli Lilly made up 0.36% of Armstrong Fleming & Moore's portfolio in Q1 2026, its #45 holding.
Armstrong Fleming & Moore first reported a position in Eli Lilly in Q2 2023 and has held it in 12 quarters since.
Armstrong Fleming & Moore's Eli Lilly position peaked at $963K in Q4 2025.
4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Armstrong Fleming & Moore's 13F filing for Q1 2026, filed 13 Apr 2026.